Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2024

Open Access 01-12-2024 | Melanoma | Review

Roles and mechanisms of aberrant alternative splicing in melanoma — implications for targeted therapy and immunotherapy resistance

Authors: Wanxian Chen, Deyi Geng, Jiasheng Chen, Xiaosha Han, Qihu Xie, Genghong Guo, Xuefen Chen, Wancong Zhang, Shijie Tang, Xiaoping Zhong

Published in: Cancer Cell International | Issue 1/2024

Login to get access

Abstract

Background

Despite advances in therapeutic strategies, resistance to immunotherapy and the off-target effects of targeted therapy have significantly weakened the benefits for patients with melanoma.

Main body

Alternative splicing plays a crucial role in transcriptional reprogramming during melanoma development. In particular, aberrant alternative splicing is involved in the efficacy of immunotherapy, targeted therapy, and melanoma metastasis. Abnormal expression of splicing factors and variants may serve as biomarkers or therapeutic targets for the diagnosis and prognosis of melanoma. Therefore, comprehensively integrating their roles and related mechanisms is essential. This review provides the first detailed summary of the splicing process in melanoma and the changes occurring in this pathway.

Conclusion

The focus of this review is to provide strategies for developing novel diagnostic biomarkers and summarize their potential to alter resistance to targeted therapies and immunotherapy.
Literature
1.
2.
Kabbarah O, Chin L. Revealing the genomic heterogeneity of melanoma. Cancer Cell. 2005;8(6):439–41.PubMedCrossRef
3.
4.
Leonardi GC, Falzone L, Salemi R, Zanghì A, Spandidos DA, Mccubrey JA, et al. Cutaneous melanoma: from pathogenesis to therapy (review). Int J Oncol. 2018;52(4):1071–80.PubMedPubMedCentral
5.
Robert C, Grob JJ, Stroyakovskiy D, Karaszewska B, Hauschild A, Levchenko E, et al. Five-year outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. N Engl J Med. 2019;381(7):626–36.PubMedCrossRef
6.
Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol. 2019;30(4):582–8.PubMedPubMedCentralCrossRef
7.
8.
Arozarena I, Wellbrock C. Phenotype plasticity as enabler of melanoma progression and therapy resistance. Nat Rev Cancer. 2019;19(7):377–91.PubMedCrossRef
9.
Benito-Jardón L, Díaz-Martínez M, Arellano-Sánchez N, Vaquero-Morales P, Esparís-Ogando A, Teixidó J. Resistance to MAPK inhibitors in Melanoma involves activation of the IGF1R-MEK5-Erk5 pathway. Cancer Res. 2019;79(9):2244–56.PubMedCrossRef
10.
Lee JH, Shklovskaya E, Lim SY, Carlino MS, Menzies AM, Stewart A, et al. Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition. Nat Commun. 2020;11(1):1897.ADSPubMedPubMedCentralCrossRef
11.
Kahles A, Lehmann KV, Toussaint NC, Hüser M, Stark SG, Sachsenberg T, et al. Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 patients. Cancer Cell. 2018;34(2):211–224e6.PubMedPubMedCentralCrossRef
12.
13.
14.
15.
Sciarrillo R, Wojtuszkiewicz A, Assaraf YG, Jansen G, Kaspers GJL, Giovannetti E, et al. The role of alternative splicing in cancer: from oncogenesis to drug resistance. Drug Resist Updat. 2020;53:100728.PubMedCrossRef
16.
North K, Benbarche S, Liu B, Pangallo J, Chen S, Stahl M, et al. Synthetic introns enable splicing factor mutation-dependent targeting of cancer cells. Nat Biotechnol. 2022;40(7):1103–13.PubMedPubMedCentralCrossRef
17.
Bonnal SC, López-Oreja I, Valcárcel J. Roles and mechanisms of alternative splicing in cancer - implications for care. Nat Rev Clin Oncol. 2020;17(8):457–74.PubMedCrossRef
18.
19.
Sebestyén E, Singh B, Miñana B, Pagès A, Mateo F, Pujana MA, et al. Large-scale analysis of genome and transcriptome alterations in multiple tumors unveils novel cancer-relevant splicing networks. Genome Res. 2016;26(6):732–44.PubMedPubMedCentralCrossRef
20.
Stark R, Grzelak M, Hadfield J. RNA sequencing: the teenage years. Nat Rev Genet. 2019;20(11):631–56.PubMedCrossRef
21.
22.
Zhang X, Yan C, Hang J, Finci LI, Lei J, Shi Y. An atomic structure of the human spliceosome. Cell. 2017;169(5):918–929e14.PubMedCrossRef
23.
24.
25.
26.
Änkö ML. Regulation of gene expression programmes by serine-arginine rich splicing factors. Semin Cell Dev Biol. 2014;32:11–21.PubMedCrossRef
27.
Long JC, Caceres JF. The SR protein family of splicing factors: master regulators of gene expression. Biochem J. 2009;417(1):15–27.PubMedCrossRef
28.
Busch A, Hertel KJ. Evolution of SR protein and hnRNP splicing regulatory factors. Wiley Interdiscip Rev RNA. 2012;3(1):1–12.PubMedCrossRef
29.
30.
Jin C, Dong D, Yang Z, Xia R, Tao S, Piao M. CircMYC regulates glycolysis and cell proliferation in Melanoma. Cell Biochem Biophys. 2020;78(1):77–88.PubMedCrossRef
31.
Gammons MV, Lucas R, Dean R, Coupland SE, Oltean S, Bates DO. Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanoma. Br J Cancer. 2014;111(3):477–85.PubMedPubMedCentralCrossRef
32.
Moreira GA, Lima GD, de Siqueira A, Barros RP, de Adjanohoun MV, Santos ALM. Antimetastatic effect of the pharmacological inhibition of serine/arginine-rich protein kinases (SRPK) in murine melanoma. Toxicol Appl Pharmacol. 2018;356:214–23.PubMedCrossRef
33.
Caetano MMM, Moreira GA, da Silva MR, Guimarães GR, Santos L, de de O, Pacheco A. Impaired expression of serine/arginine protein kinase 2 (SRPK2) affects melanoma progression. Front Genet. 2022;13:979735.PubMedPubMedCentralCrossRef
34.
Moreira GA, Caetano MMM, do Vale JA, de Paiva JC, Gonçalves VHS, Almeida AA, et al. The SRPK inhibitor N-(2-(piperidin-1-yl)-5-(trifluoromethyl)phenyl) isonicotinamide (SRPIN340) increases the immune response against metastatic melanoma in mice. Biochem Pharmacol. 2022;203:115161.PubMedCrossRef
35.
Tang Y, Horikawa I, Ajiro M, Robles AI, Fujita K, Mondal AM, et al. Downregulation of splicing factor SRSF3 induces p53β, an alternatively spliced isoform of p53 that promotes cellular senescence. Oncogene. 2013;32(22):2792–8.PubMedCrossRef
36.
Corbo C, Orrù S, Salvatore F. SRp20: an overview of its role in human diseases. Biochem Biophys Res Commun. 2013;436(1):1–5.PubMedCrossRef
37.
Dewaele M, Tabaglio T, Willekens K, Bezzi M, Teo SX, Low DHP, et al. Antisense oligonucleotide-mediated MDM4 exon 6 skipping impairs tumor growth. J Clin Invest. 2016;126(1):68–84.PubMedCrossRef
38.
Jiang CC, Lai F, Tay KH, Croft A, Rizos H, Becker TM, et al. Apoptosis of human melanoma cells induced by inhibition of B-RAFV600E involves preferential splicing of bimS. Cell Death Dis. 2010;1(9):e69.PubMedPubMedCentralCrossRef
39.
Lai F, Jiang CC, Farrelly ML, Zhang XD, Hersey P. Evidence for upregulation of Bim and the splicing factor SRp55 in melanoma cells from patients treated with selective BRAF inhibitors. Melanoma Res. 2012;22(3):244–51.PubMedCrossRef
40.
41.
Dreyfuss G, Matunis MJ, Piñol-Roma S, Burd CG. hnRNP proteins and the biogenesis of mRNA. Annu Rev Biochem. 1993;62:289–321.PubMedCrossRef
42.
Golan-Gerstl R, Cohen M, Shilo A, Suh SS, Bakàcs A, Coppola L, et al. Splicing factor hnRNP A2/B1 regulates tumor suppressor gene splicing and is an oncogenic driver in glioblastoma. Cancer Res. 2011;71(13):4464–72.PubMedCrossRef
43.
Clower CV, Chatterjee D, Wang Z, Cantley LC, Vander Heiden MG, Krainer AR. The alternative splicing repressors hnRNP A1/A2 and PTB influence pyruvate kinase isoform expression and cell metabolism. Proc Natl Acad Sci U S A. 2010;107(5):1894–9.ADSPubMedPubMedCentralCrossRef
44.
Babic I, Anderson ES, Tanaka K, Guo D, Masui K, Li B, et al. EGFR mutation-induced alternative splicing of Max contributes to growth of glycolytic tumors in brain cancer. Cell Metab. 2013;17(6):1000–8.PubMedPubMedCentralCrossRef
45.
David CJ, Chen M, Assanah M, Canoll P, Manley JL. HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature. 2010;463(7279):364–8.ADSPubMedCrossRef
46.
47.
Geng G, Xu C, Peng N, Li Y, Liu J, Wu J, et al. PTBP1 is necessary for dendritic cells to regulate T-cell homeostasis and antitumour immunity. Immunology. 2021;163(1):74–85.PubMedPubMedCentralCrossRef
48.
Huang Q, Gu S, Fang J, Li X, Lin L. A pan-cancer analysis of the oncogenic role of polypyrimidine tract binding protein 1 (PTBP1) in human tumors. Med (Baltim). 2022;101(52):e32428.CrossRef
49.
Ladányi A, Rásó E, Barbai T, Vízkeleti L, Puskás LG, Kovács SA, et al. Identification of a Tumor Cell Associated Type I IFN Resistance Gene expression signature of human melanoma, the components of which have a predictive potential for Immunotherapy. Int J Mol Sci. 2022;23(5):2704.PubMedPubMedCentralCrossRef
50.
Marzese DM, Liu M, Huynh JL, Hirose H, Donovan NC, Huynh KT, et al. Brain metastasis is predetermined in early stages of cutaneous melanoma by CD44v6 expression through epigenetic regulation of the spliceosome. Pigment Cell Melanoma Res. 2015;28(1):82–93.PubMedCrossRef
51.
Charpentier M, Dupré E, Fortun A, Briand F, Maillasson M, Com E, et al. hnRNP-A1 binds to the IRES of MELOE-1 antigen to promote MELOE-1 translation in stressed melanoma cells. Mol Oncol. 2022;16(3):594–606.PubMedCrossRef
52.
53.
54.
Coa LL, Abreu TF, Tashima AK, Green J, Pascon RC, Vallim MA, et al. AKT/protein kinase B associates with β-actin in the nucleus of melanoma cells. Biosci Rep. 2019;39(1):BSR20181312.PubMedPubMedCentralCrossRef
55.
Cretu C, Schmitzová J, Ponce-Salvatierra A, Dybkov O, De Laurentiis EI, Sharma K, et al. Molecular Architecture of SF3b and Structural consequences of its Cancer-related mutations. Mol Cell. 2016;64(2):307–19.PubMedCrossRef
56.
Will CL, Urlaub H, Achsel T, Gentzel M, Wilm M, Lührmann R. Characterization of novel SF3b and 17S U2 snRNP proteins, including a human Prp5p homologue and an SF3b DEAD-box protein. EMBO J. 2002;21(18):4978–88.PubMedPubMedCentralCrossRef
57.
58.
Kanagal-Shamanna R, Montalban-Bravo G, Sasaki K, Darbaniyan F, Jabbour E, Bueso-Ramos C, et al. Only SF3B1 mutation involving K700E independently predicts overall survival in myelodysplastic syndromes. Cancer. 2021;127(19):3552–65.PubMedCrossRef
59.
Harbour JW, Roberson EDO, Anbunathan H, Onken MD, Worley LA, Bowcock AM. Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma. Nat Genet. 2013;45(2):133–5.PubMedPubMedCentralCrossRef
60.
61.
Nguyen JQN, Drabarek W, Yavuzyigitoglu S, Medico Salsench E, Verdijk RM, Naus NC, et al. Spliceosome mutations in Uveal Melanoma. Int J Mol Sci. 2020;21(24):9546.PubMedPubMedCentralCrossRef
62.
Liu B, Liu Z, Chen S, Ki M, Erickson C, Reis-Filho JS, et al. Mutant SF3B1 promotes AKT- and NF-κB-driven mammary tumorigenesis. J Clin Invest. 2021;131(1):e138315.PubMedPubMedCentralCrossRef
63.
64.
Bigot J, Lalanne AI, Lucibello F, Gueguen P, Houy A, Dayot S, et al. Splicing patterns in SF3B1-Mutated Uveal Melanoma Generate Shared Immunogenic Tumor-Specific Neoepitopes. Cancer Discov. 2021;11(8):1938–51.PubMedCrossRef
65.
Harper J, Adams KJ, Bossi G, Wright DE, Stacey AR, Bedke N, et al. An approved in vitro approach to preclinical safety and efficacy evaluation of engineered T cell receptor anti-CD3 bispecific (ImmTAC) molecules. PLoS ONE. 2018;13(10):e0205491.PubMedPubMedCentralCrossRef
66.
Liddy N, Bossi G, Adams KJ, Lissina A, Mahon TM, Hassan NJ, et al. Monoclonal TCR-redirected tumor cell killing. Nat Med. 2012;18(6):980–7.PubMedCrossRef
67.
Hluchý M, Gajdušková P, Ruiz de Los Mozos I, Rájecký M, Kluge M, Berger BT, et al. CDK11 regulates pre-mRNA splicing by phosphorylation of SF3B1. Nature. 2022;609(7928):829–34.ADSPubMedCrossRef
68.
Burbage M, Rocañín-Arjó A, Baudon B, Arribas YA, Merlotti A, Rookhuizen DC, et al. Epigenetically controlled tumor antigens derived from splice junctions between exons and transposable elements. Sci Immunol. 2023;8(80):eabm6360.PubMedCrossRef
69.
70.
Song WM, Agrawal P, Von Itter R, Fontanals-Cirera B, Wang M, Zhou X, et al. Network models of primary melanoma microenvironments identify key melanoma regulators underlying prognosis. Nat Commun. 2021;12(1):1214.ADSPubMedPubMedCentralCrossRef
71.
Wellbrock C. MAPK pathway inhibition in melanoma: resistance three ways. Biochem Soc Trans. 2014;42(4):727–32.PubMedCrossRef
72.
Lavoie H, Sahmi M, Maisonneuve P, Marullo SA, Thevakumaran N, Jin T, et al. MEK drives BRAF activation through allosteric control of KSR proteins. Nature. 2018;554(7693):549–53.ADSPubMedPubMedCentralCrossRef
73.
Pupo GM, Boyd SC, Fung C, Carlino MS, Menzies AM, Pedersen B, et al. Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing. Biomark Res. 2017;5:17.PubMedPubMedCentralCrossRef
74.
Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949–54.ADSPubMedCrossRef
75.
Roskoski R. Targeting oncogenic raf protein-serine/threonine kinases in human cancers. Pharmacol Res. 2018;135:239–58.PubMedCrossRef
76.
Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature. 2011;480(7377):387–90.ADSPubMedPubMedCentralCrossRef
77.
Salton M, Kasprzak WK, Voss T, Shapiro BA, Poulikakos PI, Misteli T. Inhibition of vemurafenib-resistant melanoma by interference with pre-mRNA splicing. Nat Commun. 2015;6:7103.ADSPubMedCrossRef
78.
Hartsough EJ, Kugel CH, Vido MJ, Berger AC, Purwin TJ, Goldberg A, et al. Response and resistance to Paradox-breaking BRAF inhibitor in Melanomas in vivo and Ex vivo. Mol Cancer Ther. 2018;17(1):84–95.PubMedCrossRef
79.
Basile KJ, Le K, Hartsough EJ, Aplin AE. Inhibition of mutant BRAF splice variant signaling by next-generation, selective RAF inhibitors. Pigment Cell Melanoma Res. 2014;27(3):479–84.PubMedPubMedCentralCrossRef
80.
Roy S, McPherson RA, Apolloni A, Yan J, Lane A, Clyde-Smith J, et al. 14-3-3 facilitates ras-dependent Raf-1 activation in vitro and in vivo. Mol Cell Biol. 1998;18(7):3947–55.PubMedPubMedCentralCrossRef
81.
Hekman M, Wiese S, Metz R, Albert S, Troppmair J, Nickel J, et al. Dynamic changes in C-Raf phosphorylation and 14-3-3 protein binding in response to growth factor stimulation: differential roles of 14-3-3 protein binding sites. J Biol Chem. 2004;279(14):14074–86.PubMedCrossRef
82.
Hmitou I, Druillennec S, Valluet A, Peyssonnaux C, Eychène A. Differential regulation of B-raf isoforms by phosphorylation and autoinhibitory mechanisms. Mol Cell Biol. 2007;27(1):31–43.PubMedCrossRef
83.
Ritt DA, Monson DM, Specht SI, Morrison DK. Impact of feedback phosphorylation and raf heterodimerization on normal and mutant B-Raf signaling. Mol Cell Biol. 2010;30(3):806–19.PubMedCrossRef
84.
Yao Z, Torres NM, Tao A, Gao Y, Luo L, Li Q, et al. BRAF mutants evade ERK-Dependent feedback by different mechanisms that determine their sensitivity to pharmacologic inhibition. Cancer Cell. 2015;28(3):370–83.PubMedPubMedCentralCrossRef
85.
86.
Vido MJ, Rock J, Aplin AE. Role of serine 365 in BRAF V600E sensitivity to RAF inhibition. Pigment Cell Melanoma Res. 2021;34(4):696–702.PubMedCrossRef
87.
McCormick F. Ras-related proteins in signal transduction and growth control. Mol Reprod Dev. 1995;42(4):500–6.PubMedCrossRef
88.
Jakob JA, Bassett RL, Ng CS, Curry JL, Joseph RW, Alvarado GC, et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer. 2012;118(16):4014–23.PubMedCrossRef
89.
Kwong LN, Costello JC, Liu H, Jiang S, Helms TL, Langsdorf AE, et al. Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nat Med. 2012;18(10):1503–10.PubMedPubMedCentralCrossRef
90.
Michielin O, van Akkooi ACJ, Ascierto PA, Dummer R, Keilholz U, ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Cutaneous melanoma: ESMO Clinical Practice guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2019;30(12):1884–901.PubMedCrossRef
91.
Guida M, Bartolomeo N, Quaglino P, Madonna G, Pigozzo J, Di Giacomo AM, et al. No impact of NRAS Mutation on features of primary and metastatic melanoma or on outcomes of checkpoint inhibitor immunotherapy: an Italian Melanoma Intergroup (IMI) Study. Cancers (Basel). 2021;13(3):475.PubMedCrossRef
92.
Thomas NE, Edmiston SN, Alexander A, Groben PA, Parrish E, Kricker A, et al. Association between NRAS and BRAF Mutational Status and Melanoma-Specific Survival among patients with higher-risk primary melanoma. JAMA Oncol. 2015;1(3):359–68.PubMedPubMedCentralCrossRef
93.
Dummer R, Schadendorf D, Ascierto PA, Arance A, Dutriaux C, Di Giacomo AM, et al. Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18(4):435–45.PubMedCrossRef
94.
Randic T, Kozar I, Margue C, Utikal J, Kreis S. NRAS mutant melanoma: towards better therapies. Cancer Treat Rev. 2021;99:102238.PubMedCrossRef
95.
Ak E, Kw SS, Cj H. W, S L, R P, NRAS isoforms differentially affect downstream pathways, cell growth, and cell transformation. Proceedings of the National Academy of Sciences of the United States of America [Internet]. 2014 Mar 18 [cited 2023 May 15];111(11). Available from: https://​pubmed.​ncbi.​nlm.​nih.​gov/​24586049/​.
96.
Burd CE, Liu W, Huynh MV, Waqas MA, Gillahan JE, Clark KS, et al. Mutation-specific RAS oncogenicity explains NRAS codon 61 selection in melanoma. Cancer Discov. 2014;4(12):1418–29.PubMedPubMedCentralCrossRef
97.
98.
99.
Duggan MC, Regan-Fendt K, Olaverria Salavaggione GN, Howard JH, Stiff AR, Sabella J, et al. Neuroblastoma RAS viral oncogene homolog mRNA is differentially spliced to give five distinct isoforms: implications for melanoma therapy. Melanoma Res. 2019;29(5):491–500.PubMedPubMedCentralCrossRef
100.
101.
102.
Mandalà M, Merelli B, Massi D. Nras in melanoma: targeting the undruggable target. Crit Rev Oncol Hematol. 2014;92(2):107–22.PubMedCrossRef
103.
Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol. 2008;9(1):47–59.PubMedCrossRef
104.
105.
Kale J, Osterlund EJ, Andrews DW. BCL-2 family proteins: changing partners in the dance towards death. Cell Death Differ. 2018;25(1):65–80.PubMedCrossRef
106.
Liu Q, Moldoveanu T, Sprules T, Matta-Camacho E, Mansur-Azzam N, Gehring K. Apoptotic regulation by MCL-1 through heterodimerization. J Biol Chem. 2010;285(25):19615–24.PubMedPubMedCentralCrossRef
107.
Ku B, Liang C, Jung JU, Oh BH. Evidence that inhibition of BAX activation by BCL-2 involves its tight and preferential interaction with the BH3 domain of BAX. Cell Res. 2011;21(4):627–41.PubMedCrossRef
108.
Czabotar PE, Westphal D, Dewson G, Ma S, Hockings C, Fairlie WD, et al. Bax crystal structures reveal how BH3 domains activate Bax and nucleate its oligomerization to induce apoptosis. Cell. 2013;152(3):519–31.PubMedCrossRef
109.
Moldoveanu T, Grace CR, Llambi F, Nourse A, Fitzgerald P, Gehring K, et al. BID-induced structural changes in BAK promote apoptosis. Nat Struct Mol Biol. 2013;20(5):589–97.PubMedPubMedCentralCrossRef
110.
111.
112.
113.
McKee CS, Hill DS, Redfern CPF, Armstrong JL, Lovat PE. Oncogenic BRAF signalling increases Mcl-1 expression in cutaneous metastatic melanoma. Exp Dermatol. 2013;22(11):767–9.PubMedCrossRef
114.
Tseng HY, Dreyer J, Emran AA, Gunatilake D, Pirozyan M, Cullinane C, et al. Co-targeting bromodomain and extra-terminal proteins and MCL1 induces synergistic cell death in melanoma. Int J Cancer. 2020;147(8):2176–89.PubMedCrossRef
115.
Aird D, Teng T, Huang CL, Pazolli E, Banka D, Cheung-Ong K, et al. Sensitivity to splicing modulation of BCL2 family genes defines cancer therapeutic strategies for splicing modulators. Nat Commun. 2019;10(1):137.ADSPubMedPubMedCentralCrossRef
116.
Sale MJ, Minihane E, Monks NR, Gilley R, Richards FM, Schifferli KP, et al. Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors. Nat Commun. 2019;10(1):5167.ADSPubMedPubMedCentralCrossRef
117.
Marine JC, Jochemsen AG. Mdmx as an essential regulator of p53 activity. Biochem Biophys Res Commun. 2005;331(3):750–60.PubMedCrossRef
118.
D D, E M, D P, D M, M C, R F, et al. Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity. Molecular and cellular biology [Internet]. 2004 Jul [cited 2023 May 15];24(13). Available from: https://​pubmed.​ncbi.​nlm.​nih.​gov/​15199139/​.
119.
120.
121.
122.
Boutz PL, Bhutkar A, Sharp PA. Detained introns are a novel, widespread class of post-transcriptionally spliced introns. Genes Dev. 2015;29(1):63–80.PubMedPubMedCentralCrossRef
123.
124.
AbuHammad S, Cullinane C, Martin C, Bacolas Z, Ward T, Chen H, et al. Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma. Proc Natl Acad Sci U S A. 2019;116(36):17990–8000.ADSPubMedPubMedCentralCrossRef
125.
Dean JL, McClendon AK, Hickey TE, Butler LM, Tilley WD, Witkiewicz AK, et al. Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors. Cell Cycle. 2012;11(14):2756–61.PubMedPubMedCentralCrossRef
126.
Herrera-Abreu MT, Palafox M, Asghar U, Rivas MA, Cutts RJ, Garcia-Murillas I, et al. Early Adaptation and Acquired Resistance to CDK4/6 inhibition in Estrogen receptor-positive breast Cancer. Cancer Res. 2016;76(8):2301–13.PubMedPubMedCentralCrossRef
127.
Yadav V, Chen SH, Yue YG, Buchanan S, Beckmann RP, Peng SB. Co-targeting BRAF and cyclin dependent kinases 4/6 for BRAF mutant cancers. Pharmacol Ther. 2015;149:139–49.PubMedCrossRef
128.
Mahgoub T, Eustace AJ, Collins DM, Walsh N, O’Donovan N, Crown J. Kinase inhibitor screening identifies CDK4 as a potential therapeutic target for melanoma. Int J Oncol. 2015;47(3):900–8.PubMedPubMedCentralCrossRef
129.
Yoshida A, Lee EK, Diehl JA. Induction of therapeutic senescence in Vemurafenib-Resistant melanoma by extended inhibition of CDK4/6. Cancer Res. 2016;76(10):2990–3002.PubMedPubMedCentralCrossRef
130.
Martin CA, Cullinane C, Kirby L, Abuhammad S, Lelliott EJ, Waldeck K, et al. Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance. Int J Cancer. 2018;142(10):2139–52.PubMedCrossRef
131.
Gembarska A, Luciani F, Fedele C, Russell EA, Dewaele M, Villar S, et al. MDM4 is a key therapeutic target in cutaneous melanoma. Nat Med. 2012;18(8):1239–47.PubMedCrossRef
132.
Valianatos G, Valcikova B, Growkova K, Verlande A, Mlcochova J, Radova L, et al. A small molecule drug promoting miRNA processing induces alternative splicing of MdmX transcript and rescues p53 activity in human cancer cells overexpressing MdmX protein. PLoS ONE. 2017;12(10):e0185801.PubMedPubMedCentralCrossRef
133.
134.
135.
Loh TJ, Moon H, Cho S, Jang H, Liu YC, Tai H, et al. CD44 alternative splicing and hnRNP A1 expression are associated with the metastasis of breast cancer. Oncol Rep. 2015;34(3):1231–8.PubMedCrossRef
136.
Rall CJ, Rustgi AK. CD44 isoform expression in primary and metastatic pancreatic adenocarcinoma. Cancer Res. 1995;55(9):1831–5.PubMed
137.
138.
Dzobo K, Sinkala M. Cancer stem cell marker CD44 plays multiple key roles in human cancers: Immune Suppression/Evasion, Drug Resistance, epithelial-mesenchymal transition, and Metastasis. OMICS. 2021;25(5):313–32.PubMedCrossRef
139.
Zhang P, Feng S, Liu G, Wang H, Fu A, Zhu H, et al. CD82 suppresses CD44 alternative splicing-dependent melanoma metastasis by mediating U2AF2 ubiquitination and degradation. Oncogene. 2016;35(38):5056–69.PubMedPubMedCentralCrossRef
140.
Mackereth CD, Madl T, Bonnal S, Simon B, Zanier K, Gasch A, et al. Multi-domain conformational selection underlies pre-mRNA splicing regulation by U2AF. Nature. 2011;475(7356):408–11.PubMedCrossRef
141.
Weitzenböck HP, Gschwendtner A, Wiesner C, Depke M, Schmidt F, Trautinger F, et al. Proteome analysis of NRF2 inhibition in melanoma reveals CD44 up-regulation and increased apoptosis resistance upon vemurafenib treatment. Cancer Med. 2022;11(4):956–67.PubMedCrossRef
142.
Qian Y, Liang X, Yang J, Zhao C, Nie W, Liu L, et al. Hyaluronan reduces Cationic Liposome-Induced toxicity and enhances the Antitumor Effect of targeted gene delivery in mice. ACS Appl Mater Interfaces. 2018;10(38):32006–16.PubMedCrossRef
143.
144.
Hammond SM, Wood MJA. Genetic therapies for RNA mis-splicing diseases. Trends Genet. 2011;27(5):196–205.PubMedCrossRef
145.
146.
147.
Bernard A, Boidot R, Végran F. Alternative splicing in Cancer and Immune cells. Cancers (Basel). 2022;14(7):1726.PubMedCrossRef
Metadata
Title
Roles and mechanisms of aberrant alternative splicing in melanoma — implications for targeted therapy and immunotherapy resistance
Authors
Wanxian Chen
Deyi Geng
Jiasheng Chen
Xiaosha Han
Qihu Xie
Genghong Guo
Xuefen Chen
Wancong Zhang
Shijie Tang
Xiaoping Zhong
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2024
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-024-03280-x

Other articles of this Issue 1/2024

Cancer Cell International 1/2024 Go to the issue

Research

RORα inhibits gastric cancer proliferation through attenuating G6PD and PFKFB3 induced glycolytic activity

Research

Anoikis-related signature predicts prognosis and characterizes immune landscape of ovarian cancer

Research

Genome-wide CRISPR screen identifies ESPL1 limits the response of gastric cancer cells to apatinib

Research

Identification of four snoRNAs (SNORD16, SNORA73B, SCARNA4, and SNORD49B) as novel non-invasive biomarkers for diagnosis of breast cancer

Research

Integrated bioinformatics analysis of SEMA3C in tongue squamous cell carcinoma using machine-learning strategies

Research

EZH2 G553C significantly increases the risk of brain metastasis from lung cancer due to salt bridge instability
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits